References
- American Cancer Society [webpage on the Internet]About Acute Myeloid Leukemia2017 Available from: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.htmlAccessed February 2, 2017
- ShahAAnderssonTMRachetBBjörkholmMLambertPCSurvival and cure of acute myeloid leukaemia in England, 1971–2006: a population-based studyBr J Haematol2013162450951623786647
- SayarHHypomethylating agents, another band-aid for the older AML patient?Austin J Cancer Clin Res2014111002
- ManganJKLugerSMSalvage therapy for relapsed or refractory acute myeloid leukemiaTher Adv Hematol201122738223556078
- RobozGJRosenblatTArellanoMInternational randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemiaJ Clin Oncol2014321919192624841975
- HawtinREStockettDEBylJWVoreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase IIPLoS One201054e1018620419121
- HochULynchJSatoYVoreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor modelsCancer Chemother Pharmacol2009641536518931998
- WalsbyEJColesSJKnapperSBurnettAKThe topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabineHaematologica201196339339921134979
- HawtinREStockettDEWongOKLundinCHelledayTFoxJAHomologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaksOncotarget20101760661921317456
- MechetnerEKyshtoobayevaAZonisSLevels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicinClin Cancer Res1998423893989516927
- BuzdarAUMarcusCSmithTLBlumenscheinGREarly and delayed clinical cardiotoxicity of doxorubicinCancer19855512276127653922612
- EvanchikMJAllenDYoburnJCSilvermanJAHochUMetabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiaz olyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agentDrug Metab Dispos200937359460119074528
- HochUEvanchikMJSilvermanJACYP450 inhibition, induction, metabolism, and routes of elimination of SNS-595, a novel cell cycle inhibitor in phase 1 clinical trialsPresented at: 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNovember 14–18, 2005Philadelphia, PA
- ScatenaCDKumerJLArbitrarioJPVoreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivoCancer Chemother Pharmacol201066588188820058009
- LancetJERavandiFRicklisRMA phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemiaLeukemia201125121808181421760592
- StuartRKCripeLDMarisMBREVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukemiaBr J Haematol2015168679680525403830
- LancetJERobozGJCripeLDA phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemiaHaematologica2015100223123725381131
- RavandiFRitchieEKSayarHVosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyLancet Oncol20151691025103626234174
- WojtackiJLewicka-NowakELeśniewski-KmakKAnthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention – review of the literatureMed Sci Monit20006241142011208348
- DennisMRussellNHillsRKVosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemiaBlood20151252923293225805811